Abstract
Combination therapy with ipilimumab plus PD-1 inhibitors has shown promising efficacy in various tumor types, demonstrating higher rates of response than either agent alone. HBM4003 is a fully human heavy chain only monoclonal antibody targeting CTLA-4, which has been engineered to deplete Treg cells and enhanced antibody-dependent cellular cytotoxicity. HBM4003 has shown preliminary clinical activity in phase (Ph) I trial in patients (pts) with advanced solid tumors. Pembrolizumab is a humanized immunoglobulin G4 monoclonal antibody against PD-1 and has been approved by FDA in various indications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
